{
    "clinical_study": {
        "@rank": "158243", 
        "arm_group": {
            "arm_group_label": "YVOIRE\u00ae contour", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is purposed to evaluate the long-term efficacy and safety of repeat treatment of\n      YVOIRE\u00ae contour injected into the anteromedial malar region in subjects who have completed\n      the LG-HACL014 study."
        }, 
        "brief_title": "Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE\u00ae Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study", 
        "condition": "Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region Who Have Completed the LG-HACL014 Study", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible subjects who have completed the LG-HACL014 study\n\n          -  Have anteromedial malar region volume loss at least a one-point worse on the MFAS\n             compared with 2 weeks after treatment in the LG-HACL014 study\n\n          -  Accept the obligation not to receive any other mid facial procedures or treatments\n             during the study\n\n          -  Signed informed consent\n\n          -  Those who fall under one of the following 3 cases\n\n               1. Males or females who are surgically sterile\n\n               2. Post-Menopausal females who are above 45 years of age and 2 years after the last\n                  menstruation\n\n               3. Fertile premenopausal females or males without having a surgical sterilization,\n                  who have agreed to use at least two contraception methods (one of the barrier\n                  methods must be included) for up to 14 days after the repeat treatment of the\n                  investigational device to avoid pregnancy\n\n        Exclusion Criteria:\n\n          -  Have a history of hypertrophic scars or keloids\n\n          -  Other criteria as identified in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119793", 
            "org_study_id": "LG-HACL015"
        }, 
        "intervention": {
            "arm_group_label": "YVOIRE\u00ae contour", 
            "description": "YVOIRE\u00ae contour injection into the anteromedial malar region", 
            "intervention_name": "YVOIRE\u00ae contour", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "doctorseo@hotmail.com", 
                "last_name": "Seo"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "yaeom@lgls.com", 
            "last_name": "Yun-Ae Eom", 
            "phone": "82-2-6924-3157"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean of MFAS score as assessed by the independent blinded rater", 
            "measure": "Mid Face Aesthetic Scale (MFAS) score", 
            "safety_issue": "No", 
            "time_frame": "2, 26, and 52 weeks after repeat treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119793"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes of MFAS score as assessed by the independent blinded rater", 
                "measure": "Mid Face Aesthetic Scale (MFAS) score", 
                "safety_issue": "No", 
                "time_frame": "2, 26, and 52 weeks after repeat treatment"
            }, 
            {
                "description": "MFAS Responder (at least a one-point improvement on the MFAS) rate as assessed by the independent blinded rater", 
                "measure": "Mid Face Aesthetic Scale (MFAS) Responder rate", 
                "safety_issue": "No", 
                "time_frame": "2, 26, and 52 weeks after repeat treatment"
            }, 
            {
                "description": "Mean of GAIS score as assessed by subject", 
                "measure": "Global Aesthetic Improvement Scale (GAIS) score", 
                "safety_issue": "No", 
                "time_frame": "2, 26, and 52 weeks after repeat treatment"
            }, 
            {
                "description": "GAIS Responder (at least a one-point improvement on the GAIS) rate as assessed by subject", 
                "measure": "Global Aesthetic Improvement Scale (GAIS) Responder rate", 
                "safety_issue": "No", 
                "time_frame": "2, 26, and 52 weeks after repeat treatment"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2015", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}